Stephan Seitz

Summary

Country: Germany

Publications

  1. doi request reprint Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition
    Stephan Seitz
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center Florida, South Florida VA Foundation for Research and Education, Florida, USA
    Anticancer Drugs 20:553-8. 2009
  2. pmc GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL, USA
    Cell Cycle 11:4203-10. 2012
  3. ncbi request reprint Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162
    Andrea Treszl
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, 1201 NW 16th Street, Miami, FL 33125, USA
    Peptides 30:1643-50. 2009
  4. ncbi request reprint Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition
    Stefan Buchholz
    The Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida VA Foundation for Research and Education, Miami, FL 33125, USA
    Int J Oncol 35:789-96. 2009
  5. pmc Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, Miami, FL, USA
    Cell Cycle 11:2518-25. 2012
  6. pmc Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL 33125, USA
    Proc Natl Acad Sci U S A 109:1655-60. 2012
  7. doi request reprint Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin
    Karoly Szepeshazi
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, University of Miami Miller School of Medicine, Miami, Florida 33125, USA
    Anticancer Drugs 19:349-58. 2008

Collaborators

Detail Information

Publications7

  1. doi request reprint Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition
    Stephan Seitz
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center Florida, South Florida VA Foundation for Research and Education, Florida, USA
    Anticancer Drugs 20:553-8. 2009
    ..Our findings support the concept of targeted chemotherapy based on cytotoxic peptide analog AN-162 for the treatment of breast cancers and other cancers expressing somatostatin receptors...
  2. pmc GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL, USA
    Cell Cycle 11:4203-10. 2012
    ..Our observations indicate that JMR-132 enhances the antiproliferative effect of S-phase-specific cytotoxic drugs by causing accumulation of tumor cells in S-phase...
  3. ncbi request reprint Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162
    Andrea Treszl
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, 1201 NW 16th Street, Miami, FL 33125, USA
    Peptides 30:1643-50. 2009
    ..Our results suggest that cytotoxic somatostatin analog AN-162 (AEZS-124) should be considered for the further development of a therapy of patients with NSCLC...
  4. ncbi request reprint Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition
    Stefan Buchholz
    The Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida VA Foundation for Research and Education, Miami, FL 33125, USA
    Int J Oncol 35:789-96. 2009
    ..Given the low toxicity and clinical availability of cetrorelix, this peptide antagonist should be considered for phase II studies in patients with advanced TNBC...
  5. pmc Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, Miami, FL, USA
    Cell Cycle 11:2518-25. 2012
    ..single substances (p < 0.05) was significantly greater. These findings support the use of RC-3940-II as an anticancer agent and may help to design clinical trials using RC-3940-II in combinations with cytotoxic agents...
  6. pmc Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL 33125, USA
    Proc Natl Acad Sci U S A 109:1655-60. 2012
    ..Our findings support the role of GHRH as an autocrine growth factor in prostate cancer and suggest that antagonists of GHRH should be considered for further development as therapy for CRPC...
  7. doi request reprint Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin
    Karoly Szepeshazi
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, University of Miami Miller School of Medicine, Miami, Florida 33125, USA
    Anticancer Drugs 19:349-58. 2008
    ..Targeting to multiple receptors enhances the efficacy of therapy. The results of our study encourage additional experimental investigations to permit the introduction of these cytotoxic analogs into clinical trials...